Teilnehmer v.l.n.r.: Peter Martin Fehr, Chur; Roger von Moos, Chur; Thomas Ruhstaller, St. Gallen;
Michael Knauer, St. Gallen; Michael Schwitter, Chur
ATI-450 – pancreatic cancer. darolutamide – metastatic hormone sensitive prostate cancer. mirvetuximab soravtansine – in ovarian cancer. KB-0742 – in MYC-amplified solid tumors. zandelisib – in relapsed/refractory follicular lymphoma. OP-1250 – in ≥4-line ER+/HER2-negative breast cancer.
Compendium (d) Compendium (f)